Last reviewed · How we verify
Cyclosporine 0.05% eye drops
Cyclosporine suppresses T-cell activation and cytokine production to reduce ocular surface inflammation in dry eye disease.
Cyclosporine suppresses T-cell activation and cytokine production to reduce ocular surface inflammation in dry eye disease. Used for Moderate to severe dry eye disease (keratoconjunctivitis sicca).
At a glance
| Generic name | Cyclosporine 0.05% eye drops |
|---|---|
| Also known as | fluorometholone 0.1% |
| Sponsor | Second Affiliated Hospital of Nanchang University |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin (protein phosphatase 2B) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Cyclosporine is a calcineurin inhibitor that blocks T-cell proliferation and the production of pro-inflammatory cytokines (IL-2, TNF-α, IFN-γ) at the ocular surface. By reducing immune-mediated inflammation, it increases tear production and improves tear film stability in patients with keratoconjunctivitis sicca (dry eye syndrome).
Approved indications
- Moderate to severe dry eye disease (keratoconjunctivitis sicca)
Common side effects
- Ocular irritation/burning
- Conjunctival hyperemia
- Blurred vision
- Foreign body sensation
Key clinical trials
- Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery (PHASE4)
- Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA) (NA)
- Tear Film Stability and Improvement of Asthenopia: Efficacy Observation of 0.05% Cyclosporine in Dry Eye Patients With Short BUT (NA)
- Efficacy of 0.05% Cyclosporine A Eye Drops Combined With Absorbable Tear Duct Plugs in the Treatment of Dry Eye in Sjögren's Syndrom (NA)
- A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease (PHASE2)
- Once-daily Fluorometholone vs Twice-daily Cyclosporine in Dry Eye Disease (PHASE4)
- The Effect of 0.05% CsA Eye Drops on Diabetic Patients with Dry Eye Disease (PHASE4)
- Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |